Combination treatment of PARP inhibitor, BMN 673 and DNMT inhibitor, Azacytidine: A potential therapy for BRCA negative and positive, triple negative breast cancers

被引：0
|
作者：
Chowdhury, Khadiza [1 ]
Lapidus, Rena G. [1 ]
Choi, Eun Yong [1 ]
Baylin, Stephen [2 ]
Rassool, Feyruz V. [1 ]
机构：
[1] Univ Maryland, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2948
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2948
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer
    Eskiler, G. Guney
    Cecener, G.
    Egeli, U.
    Tunca, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile
    Eskiler, Gamze Guney
    Cecener, Gulsah
    Egeli, Unal
    Tunca, Berrin
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2019, 33 (05)
  • [3] Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer
    Pulliam, Nicholas
    Taverna, Pietro
    Lyons, John
    Nephew, Kenneth P.
    CANCER RESEARCH, 2015, 75
  • [4] Decreased Fanconi anemia gene expression contributes to efficacy of PARP and DNMT inhibitor combination therapy in triple negative breast cancer
    McLaughlin, Lena J.
    Li, Huili
    Nagaria, Pratik
    Baylin, Stephen B.
    Zahnow, Cynthia A.
    Rassool, Feyruz V.
    CANCER RESEARCH, 2017, 77
  • [5] A novel combination therapy with histone deacetylase inhibitor and Aurora kinase inhibitor for "triple negative" breast cancers
    Samuel, T.
    Fiskus, W.
    Buser, C.
    Bhalla, K.
    CANCER RESEARCH, 2009, 69 (02) : 91S - 92S
  • [6] DNMT and PARP inhibitor combination therapy induces an interferon-driven homologous recombination defect in triple-negative breast cancers and acute myeloid leukemia
    McLaughlin, Lena J.
    Kogan, Aksinija A.
    Choi, Eun Yong
    Lapidus, Rena S.
    Zou, Ying
    Li, Huili
    Baylin, Stephen B.
    Topper, Michael J.
    Rassool, Feyruz V.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Characterization of PARP inhibitor combination therapies in triple-negative breast cancer
    Fyle, Elicia
    Abdesselam, Djihane
    Frederick, Mallory
    Hassan, Saima N.
    CANCER RESEARCH, 2023, 84 (06)
  • [8] BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy
    Soni, Aashish
    Lin, Xixi
    Mladenov, Emil
    Mladenova, Veronika
    Stuschke, Martin
    Iliakis, George
    CANCERS, 2022, 14 (22)
  • [9] BMN 673 is a PARP inhibitor in clinical development for the treatment of breast cancer patients with deleterious germline BRCA 1 and 2 mutations
    Mina, L. A.
    Ramanathan, R. K.
    Wainberg, Z. A.
    Byers, L. A.
    Chugh, R.
    Sachdev, J. C.
    Matei, D.
    Zhang, C.
    Henshaw, J. W.
    Dorr, A.
    Kaye, S. B.
    de Bono, J. S.
    CANCER RESEARCH, 2013, 73
  • [10] Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
    Sankaranarayanan, Ramya Ambur
    Peil, Jennifer
    Vogg, Andreas T. J.
    Bolm, Carsten
    Terhorst, Steven
    Classen, Arno
    Bauwens, Matthias
    Maurer, Jochen
    Mottaghy, Felix
    Morgenroth, Agnieszka
    CANCERS, 2022, 14 (01)
12345